Granted Patent B2

US 12,383,631 · App. 18/113,413 · Granted Aug 12, 2025

Inventors: Vijaya Raghavan Pattabiraman (Volketswil, CH); Bertolt Kreft (Kleinmachow, DE); Jean-Philippe Carralot (Saint-Louis, FR); Arnaud Goepfert (Sierentz, FR); Kea Martin (Istein, DE); Andrew Chi (San Diego, CA)

Assignee: Bright Peak Therapeutics AG

A61K47/6849A61K47/6813

Abstract

Claims (35)

1. An immunocytokine composition, comprising:

an IL-18 polypeptide, wherein the IL-18 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 30; and

an antibody or an antigen binding fragment thereof specific for an immune cell associated antigen; and

a linker, wherein the linker comprises:

a first point of attachment to the IL-18 polypeptide; and

a second point of attachment to the antibody or antigen binding fragment thereof.

2. The immunocytokine composition of claim 1 , wherein the linker comprises a polymer.

3. The immunocytokine composition of claim 1 , wherein the first point of attachment is at a residue which is not the N-terminus or the C-terminus of the IL-18 polypeptide.

4. The immunocytokine composition of claim 1 , wherein the first point of attachment is at residue 68 of the IL-18 polypeptide.

5. The immunocytokine composition of claim 1 , wherein the second point of attachment is at an amino acid residue in an Fc region of the antibody or antigen binding fragment.

6. The immunocytokine composition of claim 5 , wherein the linker is covalently attached at Lys 248 of the Fc region of the antibody, wherein amino acid residue position number is based on EU numbering.

7. The immunocytokine composition of claim 1 , wherein the IL-18 polypeptide displays reduced binding to IL-18 binding protein (IL-18BP) compared to the wild type IL-18 polypeptide of SEQ ID NO: 1.

8. The immunocytokine composition of claim 1 , wherein the antibody or antigen binding fragment thereof is a monoclonal antibody.

9. The immunocytokine composition of claim 1 , wherein the antibody or antigen binding fragment thereof comprises an IgG1 or an IgG4.

10. The immunocytokine composition of claim 1 , wherein the immune cell associated antigen is programmed cell death protein 1 (PD-1).

11. The immunocytokine composition of claim 10 , wherein the antibody or antigen binding fragment thereof comprises nivolumab, pembrolizumab, LZM-009, or cemiplimab.

12. The immunocytokine composition of claim 1 , wherein the immune cell associated antigen is programmed death-ligand 1 (PD-L1).

13. The immunocytokine composition of claim 12 , wherein the antibody is durvalumab, atezolizumab, or avelumab.

14. An immunocytokine composition, comprising:

an IL-18 polypeptide having the amino acid sequence set forth in SEQ ID NO: 30;

an antibody or an antigen binding fragment thereof comprising an Fc region and having a heavy chain variable region (VH) comprising the amino acid sequence set forth in SEQ ID NO: 376 and a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NO: 377; and

a linker, wherein the linker comprises:

a first point of attachment to residue C68 of the IL-18 polypeptide; and

a second point of attachment to the antibody or antigen binding fragment thereof at Lys 248 of the Fc region, wherein amino acid residue position number is based on EU numbering.

15. The immunocytokine composition of claim 14 , wherein the antibody or antigen binding fragment thereof is LZM-009.

16. The immunocytokine composition of claim 14 , wherein the linker comprises polyethylene glycol.

17. An immunocytokine composition, comprising:

an IL-18 polypeptide having the amino acid sequence set forth in SEQ ID NO: 30;

an antibody or an antigen binding fragment thereof specific for programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1); and

a linker, wherein the linker comprises:

a first point of attachment to residue C68 the IL-18 polypeptide; and

a second point of attachment to the antibody or antigen binding fragment thereof.

18. The immunocytokine composition of claim 17 , wherein the antibody or antigen binding fragment thereof is specific for PD-1.

19. The immunocytokine composition of claim 18 , wherein the antibody or antigen binding fragment thereof comprises an Fc region, and wherein the second point of attachment to the antibody or antigen binding fragment thereof is Lys 248 of the Fc region, wherein amino acid residue position number is based on EU numbering.

20. The immunocytokine composition of claim 19 , wherein the antibody or antigen binding fragment thereof comprises an IgG1 or an IgG4.

Assignments (1)

Continuity (3)

References Cited (185)